Rexgenero’s therapies draw on an extensive research of the fundamental science of cell therapies. They have been developed by the Andalusian Health Authority through the Andalusian Initiative of Advanced Therapies [IATI] which form a network of biomedical research facilities.

IATA is a global leader in advanced therapies and has sponsored over 20 ongoing and completed clinical trials in the areas of cardiology, peripheral vascular disease, neurology, haematology, gastroenterology, ophthalmology and infectious diseases and operates 10 GMP facilities for advanced therapies in Andalusia.

Our licence partners Servicio Andaluz de Salud (SAS), the Andalusian Regional Ministry of Health, and Fundación Progreso y Salud (FPS), which is part of the Andalusian Regional Ministry of Health, a part of this network.